Therapeutic potentials of fasudil in liver fibrosis

doi:10.3748/wjg.v27.i45.7859

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 45

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4208)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

277

WORD

133

HTML

2472

Figures (1-1)

363

Sum=3245

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

382

Download

570

Sum=952

Dec 7, 2021 (publication date) through Dec 4, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Dec 7, 2021; 27(45): 7859-7861
Published online Dec 7, 2021. doi: 10.3748/wjg.v27.i45.7859

Open in New Tab Full Size Figure Download Figure

Figure 1 Schematic illustration depicting that fasudi prevents and treats liver fibrosis by activating natural killer cells and inhibiting hepatic stellate cells proliferation. NK: Natural killer; HSCs: Hepatic stellate cells.

Citation: Xi Y, Xu PF. Therapeutic potentials of fasudil in liver fibrosis. World J Gastroenterol 2021; 27(45): 7859-7861
URL: https://www.wjgnet.com/1007-9327/full/v27/i45/7859.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i45.7859